[Demyelinating neuropathy during anti-TNF alpha treatment with a review of the literature]. / Neuropathie démyélinisante au cours d'un traitement par anti-TNF alpha et revue de la littérature.
Rev Neurol (Paris)
; 163(12): 1232-5, 2007 Dec.
Article
in Fr
| MEDLINE
| ID: mdl-18355471
ABSTRACT
INTRODUCTION:
Tumor necrosis factor- (TNF) blockers are efficient in the treatment of autoimmune disorders such as inflammatory bowel disease and rheumatoid arthritis, but can induce CNS adverse effects including retrobulbar optic neuritis or aggravation of multiple sclerosis. OBSERVATION We report a case of progressive demyelinating polyneuropathy after initiation of Adalimumab (Humira). Corticosteroid and intravenous immunoglobulins were ineffective but the neuropathy improved within six months after adalimunab discontinuation.DISCUSSION:
This case, and other reports recently published suggest that anti-TNF alpha drugs can induce demyelinating neuropathy.CONCLUSION:
Clinicians should be on the lookout for signs evocating neuropathy in patients given anti TNF alpha.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Polyradiculoneuropathy
/
Tumor Necrosis Factor-alpha
/
Anti-Inflammatory Agents
/
Antibodies, Monoclonal
Limits:
Aged
/
Female
/
Humans
Language:
Fr
Journal:
Rev Neurol (Paris)
Year:
2007
Type:
Article